Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-21-021092
Filing Date
2021-03-16
Accepted
2021-03-16 18:50:19
Documents
1
Period of Report
2021-03-16

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 7611
  Complete submission text file 0001209191-21-021092.txt   9083
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Issuer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address
Hansen Gwenn (Reporting) CIK: 0001817160 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39398 | Film No.: 21747636